FDA Approves Sanofi's Subcutaneous Sarclisa Escena, First Anticancer Therapy via On-Body Injector

FDA Approves Sanofi's Subcutaneous Sarclisa Escena, First Anticancer Therapy via On-Body Injector

On July 9, 2026, the U.S. Food and Drug Administration (FDA) approved Sanofi's Sarclisa Escena (isatuximab-irfc) for subcutaneous (SC) injection across all currently approved multiple myeloma indications. The approval represents a major milestone in oncology drug delivery: Sarclisa Escena is the first-ever anticancer treatment approved to be administered via a hands-free, on-body delivery system (injector).

Clinical Evidence and Delivery Innovation

The FDA's decision was supported by noninferiority data from the Phase 3 IRAKLIA clinical trial, which compared the subcutaneous formulation to the standard intravenous (IV) infusion. The trial demonstrated that subcutaneous isatuximab delivered via the on-body system matched the efficacy of the IV formulation while significantly reducing treatment burden and infusion-related reactions.

Rather than undergoing hours of intravenous infusions in a clinic, patients can receive the subcutaneous dose via a small, automated on-body injector¹ that adheres to the skin, delivering the therapy hands-free. This approach significantly reduces administration time from several hours down to approximately 10 minutes.

Upping anti-CD38 Competition in Myeloma

Sarclisa is a monoclonal antibody that targets the CD38 receptor on multiple myeloma cells. With this subcutaneous approval, Sanofi directly intensifies its clinical and commercial competition against Johnson & Johnson's blockbuster anti-CD38 therapy, Darzalex Faspro (daratumumab and hyaluronidase-fihj), which has dominated the subcutaneous multiple myeloma market.

The hands-free on-body injector is expected to serve as a key differentiator for Sanofi, offering patients and healthcare providers a highly convenient, clinic-independent administration alternative.